Oxaliplatin Treatment Alters Systemic Immune Responses

Figure 6

Effects of oxaliplatin treatment on T cell populations within the thymus and progenitor cells in the bone marrow. To determine any changes in the proportions of double-positive and single-positive thymocytes, we gated on CD4⁺ CD8⁺ events. No significant changes were observed in the proportion of double-positive CD4⁺ CD8⁺ thymocytes following oxaliplatin treatment when compared to the vehicle-treated cohort (a). No significant differences were observed in the proportion of single-positive CD4⁺ thymocytes following oxaliplatin treatment when compared to the vehicle-treated cohort (b). Oxaliplatin treatment caused a significant increase in the proportion single-positive CD8⁺ thymocytes following oxaliplatin treatment when compared to the vehicle-treated cohort (c). To determine any changes in the proportions of bone marrow hematopoietic stem and progenitor cells, we gated on Lin^-/CD117⁺/Sca-1⁺ events. There were no significant differences in the proportion of Lin^-/CD117⁺/Sca-1⁺ cells following oxaliplatin treatment when compared to the vehicle-treated cohort (d). N=5/group; P<0.01.

(a)

(b)

(c)

(d)